Hepatitis C virus resistance to new specifically-targeted antiviral therapy:A public health perspective

• 作者: Alicia Forcada F Xavier López-Labrador Karina Salvatierra Sabrina Fareleski
• 来源期刊: 世界病毒学杂志
• 学科: 医学
• 关键词: Specifically-targeted ANTIVIRAL therapy Direct-acting ANTIVIRAL PROTEASE INHIBITORS POLYMERASE INHIBITORS Viral resistance
• 年，卷（期）: 2013,（1）
• 页码范围: 6-15
• 页数: 10页
• 分类号: R

摘要

Until very recently,treatment for chronic hepatitis C virus(HCV)infection has been based on the combination of two non-viral specific drugs:pegylated interferon-αand ribavirin,which is effective in,overall,about 40%-50%of cases.To improve the response to treatment,novel drugs have been designed to specifically block viral proteins.Multiple compounds are under development,and the approval for clinical use of the first of such direct-acting antivirals in 2011(Telaprevir and Boceprevir),represents a milestone in HCV treatment.HCV therapeutics is entering a new expanding era,and a highly-effective cure is envisioned for the first time since the discovery of the virus in 1989.However,any antiviral treatment may be limited by the capacity of the virus to overcome the selective pressure of new drugs,generating antiviral resistance.Here,we try to provide a basic overview of new treatments,HCV resistance to new antivirals and some considerations derived from a Public Health perspective,using HCV resistance to protease and polymerase inhibitors as examples.